drugset / Trial / NCT04547621

HSRT and IMRT Chemoradiotherapy for Newly Diagnosed GBM

NCT04547621

Phase 1/2 Unknown 50 enrolled Huashan Hospital
NaSingle-groupOpen-labelTreatment

Summary

This study aims to evaluate the safety and effectiveness of the combination of 30Gy/5fx HSRT and 20Gy/10fx IMRT adjuvant therapy. The total biological effective dose (BED) of the PTV is 72 Gy in a ratio of alpha/beta ratio of 3, which equals to the conventional 60Gy/30fx treatment. This study can provide evidence for future non-inferiority phase III randomized controlled trials. The abbreviated course of radiotherapy can reduce the treatment time by half, benefit patients, and utilize the health resource.

Timeline

Start
2020-09-01
Primary completion
2023-01-01
Completion
2024-01-01

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Temozolomide Small molecule 75 mg/m2 Oral

Indications